

# Elucidating the molecular action of synthetic heat shock protein 90 inhibitors in prostate cancer

by

Heather Krista Armstrong (B.Sc, M.Sc)

A thesis submitted to the University of Adelaide in the fulfilment of the requirements for the degree of

Doctor of Philosophy

Medicine

© Heather Krista Armstrong  
Dame Roma Mitchell Cancer Research Laboratories  
School of Medicine  
The University of Adelaide and  
South Australian Health and Medical Research Institute

April 2016

## Table of Contents

Abstract .....	6
Declaration .....	8
Acknowledgements .....	9
CHAPTER 1:           General Introduction .....	11
1.1 Anatomy and Physiology of the Prostate Gland .....	12
Figure 1.1: Anatomy of the prostate gland.....	13
1.2 Cell Biology of the Prostate .....	14
Figure 1.2: Cellular structure of the prostate.....	15
1.3 Prostate Function.....	16
1.4 Diseases of the Prostate.....	16
1.4.1 Benign Prostatic Hyperplasia (BPH).....	16
1.4.2 Prostatitis.....	17
1.4.3 Prostate Cancer (PCa) .....	17
Figure 1.3: TNM PCa staging. ....	19
Figure 1.4: Gleason scoring. ....	20
1.5 Hormone Signalling Pathways and the Androgen Receptor in Prostate Cancer.....	22
1.6 Current Methods for the Treatment of Prostate Cancer .....	23
Figure 1.5: Androgen signalling. ....	25
1.7 Chaperone Proteins and Prostate Cancer .....	26
1.8 Hsp90 inhibitors 17-AAG and AUY922 in Prostate Cancer .....	38
1.8.1 17-Allylamino-17-demethoxygeldanamycin (17-AAG; Tanespimycin) .....	38
1.8.2 AUY922 (Luminespib) .....	38
1.9 Resistance to Currently Available Therapies .....	39
1.9.1 P-glycoprotein and NQO1/DT-diaphorase.....	39
1.9.2 Induction of the Heat Shock Response .....	39
1.9.3 Androgen Receptor Variants.....	41
1.9.4 C-terminal Hsp90 Inhibitors .....	41
1.10 Mechanism of Action of Hsp90 Inhibitors.....	42
Figure 1.6: Antitumour activity of AUY922.....	44
1.11 Summary .....	45
1.12 Thesis Objectives .....	46
CHAPTER 2:           Methods and Materials.....	47
2.1 Materials.....	48
2.1.1 Reagents .....	48

Table 2.1: Chemicals and reagents.....	48
2.1.2 Commonly Used Buffers.....	52
Table 2.2: Commonly Used Buffers and Media .....	52
2.1.3 Oligonucleotides .....	55
Table 2.3: Primers used in sequencing and RT-qPCR experiments.....	55
2.1.4 Antibodies .....	56
Table 2.4: Primary antibodies .....	56
2.2. Methods.....	57
2.2.1 Cell Culture .....	58
2.2.1.1 Maintaining and Passaging Cells .....	58
2.2.1.2 Charcoal Stripping of Fetal Calf Serum.....	58
2.2.2 Preparation of Steroid Stocks.....	58
2.2.3 Preparation of Compound Stocks.....	59
2.2.4 Western Blotting .....	59
2.2.4.1 Preparation of Cell Lysates .....	59
2.2.4.2 Bradford Assay.....	59
2.2.4.3 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE).....	59
2.2.4.4 Western Transfer and Immunoblot .....	60
2.2.5 Quantitative polymerase chain reaction (RT-qPCR) .....	60
2.2.5.1 RNA Isolation .....	60
2.2.5.2 DNase Treatment .....	60
2.2.5.3 Reverse Transcription .....	61
2.2.5.4 RT-qPCR.....	61
2.2.6 ELISA .....	62
2.2.7 Cellular Fractionation.....	62
2.2.8 Immunohistochemistry.....	62
2.2.8.1 H&E staining.....	63
2.2.8.2 Immunohistochemistry.....	63
2.2.9 Fluorescence Microscopy.....	63
2.2.10 Invasion Assay .....	64
2.2.10.1 Inverse Invasion Assay .....	64
2.2.10.2 Chick Chorioallantoic Membrane (CAM) Assay.....	64
2.2.11 Flow Cytometry .....	65
Table 2.5: Voltage settings used in flow cytometry.....	66
2.2.12 Tubulin Reassembly.....	66
CHAPTER 3: Results Section 1 Hsp90 inhibitors and cytoskeletal organisation.....	67

3.1 General Discussion .....	101
3.1.1 Invasion and migration in response to AUY922 and 17-AAG .....	101
Supplementary Figure 3.1: Inhibition of PCa cell invasion is a common response to Hsp90 inhibitors. ....	102
Supplementary Figure 3.2: Optimisation of Chorioalantoic Membrane (CAM) assay in PCa cell lines. ....	103
Supplementary Figure 3.3: E-cadherin expression is increased in response to AUY922. ....	105
3.1.3 Extended discussion of publication results .....	106
Supplementary Figure 3.4: Knock-down of fibronectin results in reduced viability in PCa cells. ....	107
Supplementary Figure 3.5: Inhibition of FN1 polymerisation by pUR4 does not affect FN1 in similar way as AUY922 .....	108
CHAPTER 4:                 Results Section 2    Role of ARVs in resistance to Hsp90 inhibitors .....	112
4.1 Introduction .....	113
4.2 Methods.....	114
4.2.1 Plasmid Vectors .....	114
4.2.2 DNA Preparation.....	114
4.2.2.1 Plasmid Preparation .....	114
Figure 4.1: p3XFLAG-CMVTM-10 expression vector .....	115
4.2.2.2 Preparation of Competent Cells .....	116
4.2.2.3 Transformation of Escherichia coli .....	116
4.2.2.4 Plasmid DNA Extraction.....	116
4.2.2.5 Determining DNA Concentration .....	117
4.2.2.6 Restriction Endonuclease Digestion.....	117
4.2.2.7 Agarose Gel Electrophoresis.....	117
4.2.2.8 DNA sequencing .....	117
4.2.3 Lentiviral Transduction of shRNA.....	118
4.2.3.1 Preparation of Lentiviral Plasmid .....	118
4.2.3.2 Transduction.....	119
Table 4.1: shRNA sequence .....	119
Figure 4.2: .....	120
4.2.4 siRNA Transfection .....	121
Table 4.2: siRNA sequence .....	121
4.2.5 Co-Immunoprecipitation (Co-IP).....	121
4.2.6 Duolink <i>In Situ</i> Proximity Ligation Assay .....	122
4.3 Results .....	122
4.3.1 Role of heat shock proteins in resistance to Hsp90 inhibitors .....	122

4.3.1.1 Optimisation of Hsp27 or Hsp70 knockdown in LNCaP cells .....	122
Figure 4.3: Puromycin kill curve. ....	123
Figure 4.4: siRNA and shRNA knockdown of Hsps. ....	124
4.3.1.2 Knockdown of Hsp27 or Hsp70 increases sensitivity of LNCaP cells to AU922 ....	125
4.3.2 Identifying chaperone proteins that interact with ARVs .....	125
4.3.2.1 Optimisation of co-immunoprecipitation .....	125
Figure 4.5: Knockdown of Hsp27 or Hsp70 in combination with AU922. ....	126
4.3.2.2 Optimisation of Duolink PLA system from OLINK .....	127
Figure 4.6: AR-chaperone interactions by co-immunoprecipitation. ....	128
Figure 4.7: Visualisation of Duolink In Situ fluorescence provided by OLINK .....	129
Figure 4.8: AR-chaperone interactions by Duolink PLA assay. ....	131
4.4 Discussion .....	133
CHAPTER 5: Results Section 3 Pre-clinical efficacy of novel C-terminal Hsp90 modulators.....	137
CHAPTER 6: General Discussion .....	172
6.1 Targeting Hsp90.....	173
6.2 Thesis findings .....	174
6.2.1 Effect of AU922 on the cytoskeleton .....	174
6.2.2 Overcoming Mechanisms of Resistance to Hsp90 inhibitors .....	176
6.3 Future Directions.....	178
6.4 Summary .....	179
Thesis References .....	181

## Abstract

One of the most common causes of cancer-related deaths for men in the developed world is prostate cancer (PCa), occurring in 1 in 5 men by the age of 85 years. Despite significant improvements in overall survival and quality of life for men suffering from PCa, approximately 10-20% of patients inevitably develop incurable castration resistant prostate cancer (CRPC). Although the androgen receptor (AR) remains a key player in disease progression, PCa is also known to depend on multiple other protein pathways. Therapies targeting the molecular chaperone Hsp90 offer advantages for the treatment of PCa as they are capable of targeting multiple protein pathways involved in PCa progression. Specifically, Hsp90 is responsible for the stabilisation, maturation and activation of over 300 client proteins, many of which are involved in PCa. First-in-class Hsp90 inhibitors, such as 17-allylamino-demethoxygeldanamycin (17-AAG), were ineffective in clinical trials however, new rationally-designed synthetic Hsp90 inhibitors, such as AUY922, have shown greater potency than 17-AAG in both cell lines and animal models. Our laboratory previously demonstrated only AUY922 and not 17AAG or DMSO is capable of reducing proliferation and inducing apoptosis in cell lines and tumour tissues cultured as explants.

The intention of this thesis was to elucidate differential molecular mechanisms of action of Hsp90 inhibitors to better understand the basis of their improved efficacy and assist in streamlining future development of inhibitor compounds for PCa. Proteomic analysis of human prostate tumour tissues cultured as explants revealed key proteins differentially regulated in response to AUY922 vs 17-AAG and DMSO and implicated cytoskeletal organization as a significant pathway involved in AUY922 efficacy. Specifically, AUY922 inhibits secretion of fibronectin due to degradation of microtubule networks which results in inhibition of secretory vesicle trafficking. This insight into the molecular mechanism of action underlying AUY922 anti-tumour activity in PCa provides a basis for further investigation into the role that AUY922 associated cytoskeletal organisation plays in inhibitor efficacy in PCa.

Investigation of mechanisms of Hsp90 inhibitor resistance focussed on examining the involvement of cytoprotective chaperone proteins Hsp27 and Hsp70, commonly upregulated in response to Hsp90 inhibitors. The techniques of co-immunoprecipitation and the Duolink *In Situ* system were optimised for use in evaluating the chaperone requirements of wild-type and variant forms of the AR, as AR variants do not contain an Hsp90 binding site and are therefore implicated in potential mechanisms of inhibitor resistance. Due to factors beyond control, only basic optimisation of these techniques was possible and further research will be required to test this hypothesis. Interestingly, use of a new series of Hsp90 inhibitors, SM253

and SM258, for the treatment of PCa cell lines and tumour explant tissues demonstrated promising pre-clinical efficacy without inducing expression of Hsp27 or Hsp70. Overall, the results provided in this thesis afford a better understanding of cellular response to specific inhibitors which will result in improved biomarkers and aid in improving our foresight into potential mechanisms of resistance which can speed the process of discovery of compounds that may be promising in the clinic.

## **Declaration**

I, Heather Armstrong, certify that the following work does not contain any material accepted for the award of any other diploma or degree granted in my name, at any tertiary educational institution. Nor is there herein any material that has been previously published or written by another person, excluding any instances where due reference has been written in the text. I further certify that at no time in the future will any part of this work be used towards any other diploma or degree, in a submission in my name, at any tertiary educational institution without receiving prior approval from the University of Adelaide and where further required, any other institution involved in the joint-award of this degree.

Subject to the provisions of the Copyright Act 1968, I consent to the following copy of my thesis to be made available for loan and photocopying once deposited to the University of Adelaide Library.

I, the author of this thesis, further acknowledge that any copyright of published works enclosed within the following thesis belongs to the copyright holder(s) of said works.

I grant permission for a digital copy of the following thesis to be made available via the University of Adelaide's digital research repository, the University Library Search and through other internet search engines, unless permission for access has been restricted by the University of Adelaide for a period of time.

Heather Armstrong

April 2016

## Acknowledgements

There are many people I would like to thank, for the time and effort they have offered me throughout the duration of my PhD studies. To start at the very beginning, my first thanks goes to the one person who drove me to pursue a career in medical research, Dr. Paul LaPointe. Your continued personal and professional support and guidance over the years, combined with your excitement to share your knowledge, teach and take time for those around you demonstrates the type of Professor I one day hope to become. I would also like to gratefully acknowledge my PhD supervisors, Dr. Lisa Butler, Dr. Luke Selth and Dr. Margaret Centenera for the opportunity to expand my experience in the field of clinical research while completing my PhD. Without the three of you, I would not have been able to achieve all that I have; from your support at conferences and talks to your help in preparing reviews, grants, lectures, and publications. I would also like to extend this thanks to the other members of Dame Roma Mitchell Cancer Research Laboratories, South Australian Health and Medical Research Institute Cancer Theme and other members of the Department of Medicine and Faculty of Health Sciences at the University of Adelaide.

There are a number of people from these institutes who were involved in ensuring that every part of my degree ran smoothly and in maintaining a pleasant work environment, and for this I am very thankful. To those who were always available to discuss ideas, joke about lab rage, or get out of work for an hour or two, I can't explain how much your time has meant to me, you were a pleasure to work with; Tanja Jankovic-Karasoulos, Adrienne Hanson, Natalie Ryan, Marie Pickering, Lisa Philp, Swati Irani, Connie Irvine, Natasha McInnes, Suzanne Atkins, Steve Paltoglou, Geraldine Laven-Law, Jo Gillis, Marelle Hodgkinson, Isabel Coutinho and Iza Denis. Special thanks to Dr. Wayne Tilley and Dr. Theresa Hickey for challenging me to do my best and to Dr. Gerard Tarulli for your undying willingness to teach me all you know and be there to spur me on, you are one of the most inspiring post docs I have had the pleasure of working with.

The people I appreciate the very most were those I spent almost every day of my 3 years with, who were there to share in experiencing the highs and lows, successes and failures, exhaustion, frustrations, excitement and disappointments and all of life's little joys and problems with; Dr. Susan Christo, Dr. Sarah Carter, Anita Kral, Natalie Stevens, Shamika Moore, Luke Proctor, Kartini Asari, Ben Leow, Dr. Liu Lu and Vandna Sharma, you are all solely responsible for my sanity and for keeping work and studies such a fun-filled and enjoyable experience. It is also important to acknowledge all those students who spent tireless hours outside of their studies providing support and furthering the development of our peers

through the University of Adelaide Health Sciences Postgraduate Association and Tri-University committees, thank you for all of your time well spent; it was well worth the time we were able to spend with such great scientific minds including Nobel Laureates Peter Doherty and Robin Warren. On a more personal note, for all of the skype dates, visits, excursions and for being there when times were tough, I have to thank all of my friends, most especially Paulii Grzywnowicz, David Roberts, Jamie Lantz, Katrina Peters, Kevin Gardner and Alex Behnke.

My final thanks goes to the members of my family, whose love and support I could not live without. Mom, Dad, David and Kenton, words cannot explain how much your involvement in everything I do means to me, no matter if you are here with me or far away, I love you all very much. You have all made every step of this journey more enjoyable, and I will never be able to thank you enough for your continued support.